A recent Associated Press analysis highlights ongoing challenges faced by the FDA in safeguarding the U.S. drug supply, revealing significant inspection delays at pharmaceutical manufacturing plants worldwide. The slowdown in inspections since COVID-19 has raised concerns about gaps in oversight and drug safety, with lawmakers questioning the drop in violations found during inspections.

Valisure, in partnership with the Department of Defense, is addressing these challenges through independent lab testing. A recent pilot program revealed serious flaws in 10% of tested drugs, demonstrating the value of scientific testing to detect issues traditional inspections may miss.

Independent testing offers a crucial solution for ensuring drug safety and protecting public health.

‍

A recent Associated Press analysis highlights ongoing challenges faced by the FDA in safeguarding the U.S. drug supply, revealing significant inspection delays at pharmaceutical manufacturing plants worldwide. The slowdown in inspections since COVID-19 has raised concerns about gaps in oversight and drug safety, with lawmakers questioning the drop in violations found during inspections.

Valisure, in partnership with the Department of Defense, is addressing these challenges through independent lab testing. A recent pilot program revealed serious flaws in 10% of tested drugs, demonstrating the value of scientific testing to detect issues traditional inspections may miss.

Independent testing offers a crucial solution for ensuring drug safety and protecting public health.

‍